Itraconazole in the treatment of basal cell carcinoma: A case‐based review of the literature
Itraconazole is as an anti‐fungal agent with the ability to inhibit the Hedgehog signalling pathway, which makes it a candidate drug that can be repurposed for the treatment of basal cell carcinomas (BCCs). We present a case of metastatic BCC, treated with oral itraconazole 100 mg twice daily, that...
Gespeichert in:
| Veröffentlicht in: | Australasian journal of dermatology 2021-08, Vol.62 (3), p.394-397 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 397 |
|---|---|
| container_issue | 3 |
| container_start_page | 394 |
| container_title | Australasian journal of dermatology |
| container_volume | 62 |
| creator | Ip, Ken Hiu‐Kan McKerrow, Kevin |
| description | Itraconazole is as an anti‐fungal agent with the ability to inhibit the Hedgehog signalling pathway, which makes it a candidate drug that can be repurposed for the treatment of basal cell carcinomas (BCCs). We present a case of metastatic BCC, treated with oral itraconazole 100 mg twice daily, that resulted in sustained partial regression of metastatic pulmonary nodules. A systematic review on the clinical outcomes of BCCs treated with itraconazole highlights that current evidence for its clinical application remains limited and that this is the first case report where itraconazole monotherapy has achieved favourable response in metastatic BCC. |
| doi_str_mv | 10.1111/ajd.13655 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2544460196</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2564360388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3535-73d67ecfa9eabd616e35b648a268f3c58929629050e348b1839811a8918e43893</originalsourceid><addsrcrecordid>eNp10LtOwzAUBmALgWgpDLwAssQCQ1o7vtRmq8qtqBILrEROciJS5VLshKpMPALPyJPg0MKAhAdblj__OvoROqZkSP0amUU6pEwKsYP6lHMSEC3JLuoTQnigmCI9dODcghDKqBD7qMc4lUSFoo-eZo01SV2Zt7oAnFe4eQbcWDBNCVWD6wzHxpkCJ1D4zdgkr-rSXOCJvzj4fP_wz5BiC685rDre_S_yBqxpWguHaC8zhYOj7TlAj9dXD9PbYH5_M5tO5kHCBBPBmKVyDElmNJg4lVQCE7HkyoRSZSwRSodahpoIAoyrmCqmFaVGaaqAM6XZAJ1tcpe2fmnBNVGZu25mU0HduigUnHNJqJaenv6hi7q1lZ_OK8mZJEwpr843KrG1cxayaGnz0th1REnUlR750qPv0r092Sa2cQnpr_xp2YPRBqzyAtb_J0WTu8tN5BfEpYnh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564360388</pqid></control><display><type>article</type><title>Itraconazole in the treatment of basal cell carcinoma: A case‐based review of the literature</title><source>MEDLINE</source><source>Wiley Journals</source><creator>Ip, Ken Hiu‐Kan ; McKerrow, Kevin</creator><creatorcontrib>Ip, Ken Hiu‐Kan ; McKerrow, Kevin</creatorcontrib><description>Itraconazole is as an anti‐fungal agent with the ability to inhibit the Hedgehog signalling pathway, which makes it a candidate drug that can be repurposed for the treatment of basal cell carcinomas (BCCs). We present a case of metastatic BCC, treated with oral itraconazole 100 mg twice daily, that resulted in sustained partial regression of metastatic pulmonary nodules. A systematic review on the clinical outcomes of BCCs treated with itraconazole highlights that current evidence for its clinical application remains limited and that this is the first case report where itraconazole monotherapy has achieved favourable response in metastatic BCC.</description><identifier>ISSN: 0004-8380</identifier><identifier>EISSN: 1440-0960</identifier><identifier>DOI: 10.1111/ajd.13655</identifier><identifier>PMID: 34160825</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Administration, Oral ; Antineoplastic Agents - therapeutic use ; Basal cell carcinoma ; Carcinoma ; Carcinoma, Basal Cell - drug therapy ; Carcinoma, Basal Cell - pathology ; Hedgehog protein ; Hedgehog signalling pathway ; Humans ; Itraconazole ; Itraconazole - therapeutic use ; Literature reviews ; Lung nodules ; Metastases ; Metastasis ; Signal transduction ; Signal Transduction - drug effects ; Skin Neoplasms - drug therapy ; Skin Neoplasms - pathology ; Treatment Outcome</subject><ispartof>Australasian journal of dermatology, 2021-08, Vol.62 (3), p.394-397</ispartof><rights>2021 The Australasian College of Dermatologists</rights><rights>2021 The Australasian College of Dermatologists.</rights><rights>Copyright © 2021 The Australasian College of Dermatologists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3535-73d67ecfa9eabd616e35b648a268f3c58929629050e348b1839811a8918e43893</citedby><cites>FETCH-LOGICAL-c3535-73d67ecfa9eabd616e35b648a268f3c58929629050e348b1839811a8918e43893</cites><orcidid>0000-0002-6487-7982</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fajd.13655$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fajd.13655$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34160825$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ip, Ken Hiu‐Kan</creatorcontrib><creatorcontrib>McKerrow, Kevin</creatorcontrib><title>Itraconazole in the treatment of basal cell carcinoma: A case‐based review of the literature</title><title>Australasian journal of dermatology</title><addtitle>Australas J Dermatol</addtitle><description>Itraconazole is as an anti‐fungal agent with the ability to inhibit the Hedgehog signalling pathway, which makes it a candidate drug that can be repurposed for the treatment of basal cell carcinomas (BCCs). We present a case of metastatic BCC, treated with oral itraconazole 100 mg twice daily, that resulted in sustained partial regression of metastatic pulmonary nodules. A systematic review on the clinical outcomes of BCCs treated with itraconazole highlights that current evidence for its clinical application remains limited and that this is the first case report where itraconazole monotherapy has achieved favourable response in metastatic BCC.</description><subject>Administration, Oral</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Basal cell carcinoma</subject><subject>Carcinoma</subject><subject>Carcinoma, Basal Cell - drug therapy</subject><subject>Carcinoma, Basal Cell - pathology</subject><subject>Hedgehog protein</subject><subject>Hedgehog signalling pathway</subject><subject>Humans</subject><subject>Itraconazole</subject><subject>Itraconazole - therapeutic use</subject><subject>Literature reviews</subject><subject>Lung nodules</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Signal transduction</subject><subject>Signal Transduction - drug effects</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - pathology</subject><subject>Treatment Outcome</subject><issn>0004-8380</issn><issn>1440-0960</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10LtOwzAUBmALgWgpDLwAssQCQ1o7vtRmq8qtqBILrEROciJS5VLshKpMPALPyJPg0MKAhAdblj__OvoROqZkSP0amUU6pEwKsYP6lHMSEC3JLuoTQnigmCI9dODcghDKqBD7qMc4lUSFoo-eZo01SV2Zt7oAnFe4eQbcWDBNCVWD6wzHxpkCJ1D4zdgkr-rSXOCJvzj4fP_wz5BiC685rDre_S_yBqxpWguHaC8zhYOj7TlAj9dXD9PbYH5_M5tO5kHCBBPBmKVyDElmNJg4lVQCE7HkyoRSZSwRSodahpoIAoyrmCqmFaVGaaqAM6XZAJ1tcpe2fmnBNVGZu25mU0HduigUnHNJqJaenv6hi7q1lZ_OK8mZJEwpr843KrG1cxayaGnz0th1REnUlR750qPv0r092Sa2cQnpr_xp2YPRBqzyAtb_J0WTu8tN5BfEpYnh</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Ip, Ken Hiu‐Kan</creator><creator>McKerrow, Kevin</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6487-7982</orcidid></search><sort><creationdate>202108</creationdate><title>Itraconazole in the treatment of basal cell carcinoma: A case‐based review of the literature</title><author>Ip, Ken Hiu‐Kan ; McKerrow, Kevin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3535-73d67ecfa9eabd616e35b648a268f3c58929629050e348b1839811a8918e43893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Administration, Oral</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Basal cell carcinoma</topic><topic>Carcinoma</topic><topic>Carcinoma, Basal Cell - drug therapy</topic><topic>Carcinoma, Basal Cell - pathology</topic><topic>Hedgehog protein</topic><topic>Hedgehog signalling pathway</topic><topic>Humans</topic><topic>Itraconazole</topic><topic>Itraconazole - therapeutic use</topic><topic>Literature reviews</topic><topic>Lung nodules</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Signal transduction</topic><topic>Signal Transduction - drug effects</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - pathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ip, Ken Hiu‐Kan</creatorcontrib><creatorcontrib>McKerrow, Kevin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Australasian journal of dermatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ip, Ken Hiu‐Kan</au><au>McKerrow, Kevin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Itraconazole in the treatment of basal cell carcinoma: A case‐based review of the literature</atitle><jtitle>Australasian journal of dermatology</jtitle><addtitle>Australas J Dermatol</addtitle><date>2021-08</date><risdate>2021</risdate><volume>62</volume><issue>3</issue><spage>394</spage><epage>397</epage><pages>394-397</pages><issn>0004-8380</issn><eissn>1440-0960</eissn><abstract>Itraconazole is as an anti‐fungal agent with the ability to inhibit the Hedgehog signalling pathway, which makes it a candidate drug that can be repurposed for the treatment of basal cell carcinomas (BCCs). We present a case of metastatic BCC, treated with oral itraconazole 100 mg twice daily, that resulted in sustained partial regression of metastatic pulmonary nodules. A systematic review on the clinical outcomes of BCCs treated with itraconazole highlights that current evidence for its clinical application remains limited and that this is the first case report where itraconazole monotherapy has achieved favourable response in metastatic BCC.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34160825</pmid><doi>10.1111/ajd.13655</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-6487-7982</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0004-8380 |
| ispartof | Australasian journal of dermatology, 2021-08, Vol.62 (3), p.394-397 |
| issn | 0004-8380 1440-0960 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2544460196 |
| source | MEDLINE; Wiley Journals |
| subjects | Administration, Oral Antineoplastic Agents - therapeutic use Basal cell carcinoma Carcinoma Carcinoma, Basal Cell - drug therapy Carcinoma, Basal Cell - pathology Hedgehog protein Hedgehog signalling pathway Humans Itraconazole Itraconazole - therapeutic use Literature reviews Lung nodules Metastases Metastasis Signal transduction Signal Transduction - drug effects Skin Neoplasms - drug therapy Skin Neoplasms - pathology Treatment Outcome |
| title | Itraconazole in the treatment of basal cell carcinoma: A case‐based review of the literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T11%3A47%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Itraconazole%20in%20the%20treatment%20of%20basal%20cell%20carcinoma:%20A%20case%E2%80%90based%20review%20of%20the%20literature&rft.jtitle=Australasian%20journal%20of%20dermatology&rft.au=Ip,%20Ken%20Hiu%E2%80%90Kan&rft.date=2021-08&rft.volume=62&rft.issue=3&rft.spage=394&rft.epage=397&rft.pages=394-397&rft.issn=0004-8380&rft.eissn=1440-0960&rft_id=info:doi/10.1111/ajd.13655&rft_dat=%3Cproquest_cross%3E2564360388%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564360388&rft_id=info:pmid/34160825&rfr_iscdi=true |